VUZI Vuzix Corp. gains 39% Jun 28, 2019

Vuzix Corporation designs, manufactures, markets, and sells wearable display devices in the United States and internationally. The company's products are worn like eyeglasses that enable the user to view video and digital content, such as movies, computer data, the Internet, or video games. Its products include binocular wearable displays that contain two micro displays mounted in a frame attached to eyeglass-style temples or stereo headphones; monocular smart glasses products for the enterprise, industrial, and commercial markets, as well as video headphones; augmented reality products, which provide the user a live, direct or indirect, view of a physical, and real-world environment; and video viewing glasses as mobile displays for entertainment and gaming for on-the-go users, as well as support for stepping into virtual worlds, simulations, and virtual reality gaming. The company sells its products under the Vuzix brand name. Vuzix Corporation offers its products directly to consumers, as well as through specialty retailers, online retailers, distributors, resellers, and Web stores. The company was formerly known as Icuiti Corporation and changed its name to Vuzix Corporation in 2007. Vuzix Corporation was founded in 1997 and is based in West Henrietta, New York.http://www.priceseries.com/trade/VUZI-Vuzix-Corp-stock-gains-39-percent-a-Trade-Record-by-priceSeries-2019061020190628.html

STRM Streamline Health Solutions, Inc. gains 20% Jun 28, 2019

Streamline Health Solutions, Inc. provides health information technology solutions and services for hospitals and health systems in the United States and Canada. It offers computer software-based solutions through its Looking Glass platform, which captures, aggregates, and translates structured and unstructured data to deliver predictive insights to its clients. The company provides patient engagement solutions to assist clients in individual workflows, such as a patient portal, physician referral, patient eligibility and authorization, and patient scheduling, as well as patient payment, including charity management. It also offers patient care solutions that enable healthcare providers to enhance their patient care through individual workflows comprising clinical analytics, operating room management, physician portal, and care coordination; and health information management, coding, and clinical documentation improvement (CDI) solutions, which include Web-based software solutions, such as content management, release of information, computer-assisted coding, CDI, abstracting, and physician query. In addition, the company provides financial management solutions, including accounts receivable management, denials management, claims processing, spend management, and audit management; and custom integration, training, electronic image conversion, and database monitoring services. It sells its solutions and services through direct sales force and reseller partnerships. Streamline Health Solutions, Inc. was founded in 1989 and is based in Atlanta, Georgia.http://www.priceseries.com/trade/STRM-Streamline-Health-Solutions-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2019061220190628.html

ZIOP ZIOPHARM Oncology Inc gains 24% Jun 24, 2019

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon's synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.http://www.priceseries.com/trade/ZIOP-ZIOPHARM-Oncology-Inc-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2019061120190624.html

XON Intrexon Corp. gains 28% Jun 24, 2019

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.http://www.priceseries.com/trade/XON-Intrexon-Corp-stock-gains-28-percent-a-Trade-Record-by-priceSeries-2019061020190624.html

PTN Palatin Technologies, Inc. gains 16% Jun 24, 2019

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. In addition, the company is involved in the development of natriuretic peptide receptor-specific programs, including PL-3994, a natriuretic peptide receptor-A, which is in Phase II clinical studies for treatment of heart failure, acute exacerbations of asthma, and refractory hypertension. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.http://www.priceseries.com/trade/PTN-Palatin-Technologies-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019062120190624.html

CVCO Cavco Industries, Inc. gains 23% Jun 24, 2019

Cavco Industries, Inc. engages in the design, production, and retail sale of manufactured homes in the United States. It operates through two segments, Factory-Built Housing and Financial Services. The company markets its manufactured homes under the Cavco Homes, Fleetwood Homes, Palm Harbor Homes, Fairmont Homes, and Chariot Eagle brands. It also produces modular homes, including single and multi-section/modular ranch-style dwellings, split-level homes, Cape Cod style homes, two and three story homes, and multi-family units under the Nationwide Homes brand name. In addition, the company builds park model RVs and vacation cabins, as well as systems-built commercial structures, such as apartment buildings, condominiums, hotels, workforce housing, schools, and housing for U.S. military troops. Further, it offers conforming mortgages, non-conforming mortgages, and chattel loans to purchasers factory-built and site-built homes; and property and casualty insurance to owners of manufactured homes. As of April 2, 2016, the company owned and operated a network of 45 retail centers located in Oregon, Arizona, New Mexico, Texas, Oklahoma, Louisiana, Virginia, North Carolina, and Florida. It also distributes its homes through a network of independent distribution points in 44 states in the United States, Canada, Japan, and Mexico, as well as through planned community operators and residential developers. The company was founded in 1965 and is headquartered in Phoenix, Arizona.http://www.priceseries.com/trade/CVCO-Cavco-Industries-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2019052020190624.html

CIEN Ciena Corp. gains 20% Jun 24, 2019

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. The company's Networking Platforms segment offers hardware networking solutions optimized for the convergence of coherent optical transport, optical transport network switching, and packet switching. Its products include 6500 Packet-Optical Platform and the 5430 Reconfigurable Switching System, Waveserver stackable interconnect system, CoreDirector Multiservice Optical Switches, and OTN configuration for the 5410 Reconfigurable Switching System, as well as Z-Series Packet-Optical Platform; 3000 family of service delivery switches and service aggregation switches, and the 5000 family of service aggregation switches, as well as 8700 Packetwave Platform and the Ethernet packet configuration for the 5410 Service Aggregation Switch; and 4200 Advanced Services Platform, Corestream 5100/5200 Advanced Services Platform, Common Photonic Layer, and 6100 Multiservice Optical Platform. This segment also sells operating system software and enhanced software features embedded in each of these products. The company's Software and Software-Related Services segment offers network management solutions, including the OneControl Unified Management System, ON-Center Network & Service Management Suite, Ethernet Services Manager, Optical Suite Release, and Planet Operate; and Blue Planet network virtualization, service orchestration, and network management software platform, as well as related installation, support, and consulting services. Its Global Services segment provides consulting and network design, installation and deployment, maintenance support, and training services. The company sells its products through direct and indirect sales channels to network operators. Ciena Corporation was founded in 1992 and is headquartered in Hanover, Maryland.http://www.priceseries.com/trade/CIEN-Ciena-Corp-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2019060420190624.html

ROKU Roku, Inc. gains 68% Jun 21, 2019

http://www.priceseries.com/trade/ROKU-Roku-Inc-stock-gains-68-percent-a-Trade-Record-by-priceSeries-2019042520190621.html

BYSI BeyondSpring Inc. gains 28% Jun 21, 2019

N/Ahttp://www.priceseries.com/trade/BYSI-BeyondSpring-Inc-stock-gains-28-percent-a-Trade-Record-by-priceSeries-2019060720190621.html

IOVA Iovance Biotherapeutics, Inc. gains 62% Jun 4, 2019

Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; and PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is headquartered in New York, New York.http://www.priceseries.com/trade/IOVA-Iovance-Biotherapeutics-Inc-stock-gains-62-percent-a-Trade-Record-by-priceSeries-2019051520190604.html

AU AngloGold Ashanti Ltd. gains 17% Jun 4, 2019

AngloGold Ashanti Limited operates as a gold mining and exploration company. The company also produces silver, uranium oxide, copper, and sulphuric acid. Its portfolio includes 17 mines in South Africa, Continental Africa, Australasia, and the Americas. AngloGold Ashanti Limited was founded in 1944 and is headquartered in Johannesburg, South Africa.http://www.priceseries.com/trade/AU-AngloGold-Ashanti-Ltd-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2019052920190604.html

DGAZ 3X Inverse Natural Gas ETF gains 21% Jun 14, 2019

The investment seeks to replicate, net of expenses, three times the opposite (inverse) of this GSCI Natural Gas Index ER. The index comprises futures contracts on a single commodity and is calculated according to the methodology of the S&P GSCI Index.http://www.priceseries.com/trade/DGAZ-3X-Inverse-Natural-Gas-ETF-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2019053020190614.html

BRZU Direxion Daily Brazil Bull 3X S gains 15% Jun 14, 2019

http://www.priceseries.com/trade/BRZU-Direxion-Daily-Brazil-Bull-3X-S-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019052820190614.html

ARWR Arrowhead Research Corp. gains 21% Jun 14, 2019

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.http://www.priceseries.com/trade/ARWR-Arrowhead-Research-Corp-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2019052120190614.html

ADVM Adverum Biotechnologies, Inc. gains 33% Jun 14, 2019

Avalanche Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.http://www.priceseries.com/trade/ADVM-Adverum-Biotechnologies-Inc-stock-gains-33-percent-a-Trade-Record-by-priceSeries-2019051620190614.html

PDVW pdvWireless, Inc. gains 33% Jun 13, 2019

pdvWireless, Inc. operates as a private wireless communications carrier, and provider of mobile workforce communication and location based solutions in the United States. Its solutions focuses on enhancing the productivity of its customers' field-based workers, and the efficiency of their dispatch and call center operations. The company is deploying and operating dedicated, wide-area, two-way radio networks that offer private push-to-talk (PTT) communications services to primarily dispatch-centric, small and medium-sized businesses in construction, distribution, transportation, field services, waste management, and hospitality industries. It offers DispatchPlus service, which combines pdvConnect, a proprietary suite of mobile communication and workforce management applications with digital network architecture and mobile devices supplied by Motorola Solutions, Inc. The company's solution enables communication and response among field workers and streamlined dispatch operations through exchange of information by prioritizing messages from the field, which can reduce or eliminate wasteful 'on hold time'. In addition, its pdvConnect allows business customers to document field incidents and activities, and to collect operational data and location based information to enhance their operations. The company primarily markets its DispatchPlus service indirectly through Motorola's dealer network and other third-party dealers, with sales, marketing, and advertising support from its internal sales and marketing team. The company was formerly known as Pacific DataVision, Inc. and changed its name to pdvWireless, Inc. in November 2015. pdvWireless, Inc. was incorporated in 1997 and is headquartered in Woodland Park, New Jersey.http://www.priceseries.com/trade/PDVW-pdvWireless-Inc-stock-gains-33-percent-a-Trade-Record-by-priceSeries-2019041620190613.html

RNR RenaissanceRe Holdings Ltd. gains 19% Jun 11, 2019

RenaissanceRe Holdings Ltd. together with its subsidiaries, provides reinsurance and insurance coverages and related services in the United States and internationally. The company operates through Property, and Casualty and Specialty segments. The Property segment writes property catastrophe excess of loss reinsurance contracts to insure insurance and reinsurance companies against natural and man-made catastrophes, such as earthquakes, hurricanes, and tsunamis, as well as claims arising from other natural and man-made catastrophes comprising winter storms, freezes, floods, fires, windstorms, tornadoes, explosions, and acts of terrorism; and other property class of products, including proportional reinsurance, property per risk, property reinsurance, and binding facilities and regional U.S. multi-line reinsurance. The Casualty and Specialty segment underwrites various classes of products, such as accident and health, agriculture, automobile liability, aviation, casualty clash, workers' compensation, cyber, employers' liability, energy, environmental liability, marine, medical malpractice, satellite, terrorism, and umbrella or excess casualty. It also offers a range of casualty insurance products through Syndicate 1458, including general liability, medical malpractice, and professional liability. The company distributes its products and services primarily through intermediaries. RenaissanceRe Holdings Ltd. was founded in 1993 and is headquartered in Pembroke, Bermuda.http://www.priceseries.com/trade/RNR-RenaissanceRe-Holdings-Ltd-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2019041020190611.html

NBY NovaBay Pharmaceuticals, Inc. gains 15% Jun 11, 2019

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.http://www.priceseries.com/trade/NBY-NovaBay-Pharmaceuticals-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019061020190611.html

MDXG MiMedx Group, Inc gains 40% Jun 11, 2019

MiMedx Group, Inc. develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human placental tissue, skin, and bone. The company collects the donated human placental tissue and converts into a sterile product through its proprietary PURION process. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.http://www.priceseries.com/trade/MDXG-MiMedx-Group-Inc-stock-gains-40-percent-a-Trade-Record-by-priceSeries-2019052920190611.html

IDN Intellicheck Mobilisa, Inc. gains 19% Jun 11, 2019

Intellicheck Mobilisa, Inc. develops, integrates, and markets identity systems for mobile and handheld access control and security systems. The company provides identity systems products, including commercial identification products, such as IDvCheck SDK for software developers; Retail ID, an authentication solution that authenticates identification documents; IDvCheck POS, a software application that runs on various VeriFone devices; IDvCheck BHO, a browser helper object for Microsoft browser; Guest ID, a software application that speeds up check-in and ID verification at hotels and motels; AssureScan, an application, which assists pharmacies with ID verification and tracking drug related purchases; IDvCheck PC, a software solution; Age ID, a designation for various hand held devices; software products for data collection devices; and instant credit application kiosk software applications. It also offers government identification products comprising Defense ID systems to read barcodes, magnetic stripes, radio frequency identification, and optical character recognition codes printed on current forms of identification cards; Law ID, a mobile app for bona fide law enforcement officers that performs real time queries; TWIC ID Reader, an instrumental component to port security; and Visitor Center (IM 3000), a component of Defense ID system. In addition, the company performs consulting work for other companies. It serves government, military, and commercial markets through its sales force and distributors. Intellicheck Mobilisa, Inc. was founded in 1994 and is headquartered in Jericho, New York.http://www.priceseries.com/trade/IDN-Intellicheck-Mobilisa-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2019052320190611.html

CRAY Cray Inc gains 17% Jun 11, 2019

Cray Inc., together with its subsidiaries, designs, develops, manufactures, markets, and services high-performance computing systems. It operates through Supercomputing, Storage and Data Management, Maintenance and Support, and Engineering Services and Other segments. The company offers a range of supercomputing systems, including the Cray XC series, Cray XC40-AC, Cray CS400, and Cray CS-Storm supercomputers; and analytics products, such as Cray Urika-GX platform used for production-class data analytics workloads. It also provides storage and data management products comprising Cray Sonexion storage systems that embeds the Lustre parallel file system and other software in an optimal configuration; and Cray DataWarp applications accelerator. In addition, the company offers custom engineering solutions; and customer support services consisting of hardware and software maintenance, applications support, installation project management, system installation and de-installation, site preparation, and technical training for its systems, as well as ancillary services in application consulting, third-party software support, site engineering, on-site analysts for defined projects, and specialized training. It serves clients ranging from government agencies or funded research laboratories, academic institutions, and commercial entities in North America, South America, Asia, Europe, the Middle East, Australia, and Africa. The company was formerly known as Tera Computer Company and changed its name to Cray Inc. in 2000. Cray Inc. was founded in 1987 and is headquartered in Seattle, Washington.http://www.priceseries.com/trade/CRAY-Cray-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2019051520190611.html

NOVN Novan Inc gains 15% Jun 10, 2019

Novan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company's product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology. Novan, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.http://www.priceseries.com/trade/NOVN-Novan-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019053020190610.html

KTOS Kratos Defense & Security Solutions, Inc. gains 35% Jun 10, 2019

Kratos Defense & Security Solutions, Inc. provides mission critical products, solutions, and services in the United States. The company operates through three segments: Kratos Government Solutions, Unmanned Systems, and Public Safety & Security. The Kratos Government Solutions segment offers microwave electronic products; satellite communications; technical and training solutions; modular systems; and defense and rocket support services. The Unmanned Systems segment provides unmanned aerial, ground, and seaborne, as well as command, control, and communications systems. The Public Safety & Security segment designs, engineers, deploys, operates, integrates, maintains, and operates security and surveillance solutions for homeland security, public safety, critical infrastructure, government, and commercial customers. The company serves national security related agencies, the department of defense, intelligence agencies, and classified agencies, as well as international government agencies and domestic and international commercial customers; and critical infrastructure, power generation, power transport, nuclear energy, financial, IT, healthcare, education, transportation, and petro-chemical industries, as well as government and military customers. Kratos Defense & Security Solutions, Inc. was founded in 1994 and is headquartered in San Diego, California.http://www.priceseries.com/trade/KTOS-Kratos-Defense-&-Security-Solutions-Inc-stock-gains-35-percent-a-Trade-Record-by-priceSeries-2019050820190610.html

XOMA XOMA Corp. gains 43% Jun 5, 2019

XOMA Corporation discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company's product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. Its preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.http://www.priceseries.com/trade/XOMA-XOMA-Corp-stock-gains-43-percent-a-Trade-Record-by-priceSeries-2019050220190605.html

VERI Veritone, Inc. gains 25% Jun 5, 2019

N/Ahttp://www.priceseries.com/trade/VERI-Veritone-Inc-stock-gains-25-percent-a-Trade-Record-by-priceSeries-2019051420190605.html

OBLN Obalon Therapeutics Inc gains 59% Jun 5, 2019

N/Ahttp://www.priceseries.com/trade/OBLN-Obalon-Therapeutics-Inc-stock-gains-59-percent-a-Trade-Record-by-priceSeries-2019052420190605.html

AVP Avon Products, Inc. gains 15% Jun 5, 2019

Avon Products, Inc. manufactures and markets beauty and related products in Europe, the Middle East, Africa, South Latin America, North Latin America, and the Asia Pacific. The company offers beauty products, including skincare products that include personal care products, as well as fragrances and color cosmetics; and fashion and home products, such as fashion jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children's products, and nutritional products. It sells its products through direct selling by representatives. The company was founded in 1886 and is headquartered in London, the United Kingdom.http://www.priceseries.com/trade/AVP-Avon-Products-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019052020190605.html

AP Ampco-Pittsburgh Corp. gains 29% Jun 5, 2019

Ampco-Pittsburgh Corporation, together with its subsidiaries, manufactures and sells custom designed engineering products to commercial and industrial users worldwide. It operates in two segments, Forged and Cast Engineered Products, and Air and Liquid Processing. The Forged and Cast Engineered Products segment produces forged hardened steel rolls that are used in cold rolling by producers of steel, aluminum, and other metals; ingot and open die forged products for use in the oil and gas, and the aluminum and plastic extrusion industries; and cast rolls for hot and cold strip mills, medium/heavy section mills, and plate mills in various iron and steel qualities. This segment also offers forged rolls for cluster mills and Z-Hi mills; work rolls for narrow and wide strip and aluminum mills; back-up rolls for narrow strip mills; leveling rolls and shafts; and bearings, bushings, and key and keyless bearing sleeves, as well as provides a range of services, including rebuild of mill spare parts, chock inspection and repair, and onsite inspections and installations. The Air and Liquid Processing segment produces custom-engineered finned tube heat exchange coils and related heat transfer products for various industries, including OEM/commercial, fossil fuel and nuclear power generation, automotive, industrial process, and HVAC; and air handling systems for use in commercial, institutional, and industrial buildings. This segment also provides centrifugal pumps for the refrigeration, power generation, and marine defense industries. Ampco-Pittsburgh Corporation was founded in 1929 and is headquartered in Carnegie, Pennsylvania.http://www.priceseries.com/trade/AP-Ampco-Pittsburgh-Corp-stock-gains-29-percent-a-Trade-Record-by-priceSeries-2019051020190605.html

SOXS Semiconductor Bear 3X Direxion gains 37% Jun 4, 2019

http://www.priceseries.com/trade/SOXS-Semiconductor-Bear-3X-Direxion-stock-gains-37-percent-a-Trade-Record-by-priceSeries-2019050720190604.html

VTVT vTv Therapeutics Inc. gains 18% Jun 3, 2019

Biotech developing treatments for Alzheimer's disease and type 2 diabetes.http://www.priceseries.com/trade/VTVT-vTv-Therapeutics-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2019051520190603.html

GRVY GRAVITY Co., Ltd. gains 32% Jun 3, 2019

Gravity Co., Ltd. develops and publishes online games in South Korea, Japan, the United States, Canada, Taiwan, Hong Kong, Macau, China, and internationally. It offers online games; mobile games and applications; and other games and game-related products and services, including character-based merchandise and animation. The company's massively multiplayer online role playing games include Ragnarok Online, Ragnarok Online II, Requiem, Dragonica, and R.O.S.E. Online. It also provides console games and a game for Internet protocol television; and licenses the merchandizing rights of character-related products based on its online games. In addition, the company markets dolls, stationery, food, and other character-based merchandise, as well as game manuals, monthly magazines, and other publications. Further, it provides Website development and operation services; and sells goods related to mobile phones, such as ornamental accessories and USB data cables. The company was founded in 2000 and is headquartered in Seoul, South Korea. Gravity Co., Ltd. operates as a subsidiary of GungHo Online Entertainment, Inc.http://www.priceseries.com/trade/GRVY-GRAVITY-Co-Ltd-stock-gains-32-percent-a-Trade-Record-by-priceSeries-2019051020190603.html